2023-05-04 04:14:08
Pharmaceutical group Eli Lilly’s clinical trial showed a 36% reduction in cognitive decline in patients treated with donanemab
The American pharmaceutical group Eli Lilly said on Wednesday that its new treatment developed against Alzheimer’s had been shown, during a large clinical trial, to slow the progression of the disease, an announcement which paves the way for its possible authorization soon.
These results were greeted with enthusiasm by the experts, who did not hesitate to hail the entry into a “new era” for the management of Alzheimer’s disease, thanks to several recent breakthroughs.
The clinical trial, which included 1,200 participants between the ages of 60 and 85 and who had not yet reached an advanced stage of the disease, showed a 36% reduction in cognitive decline in patients treated with donanemab, according to a press release from the company.
The ability to perform everyday tasks, such as driving, conversing, having hobbies or managing finances, was also measured. Over 18 months, participants who received the treatment showed a 40% reduction in decline in their ability to perform these tasks.
Eli Lilly said he plans to file for FDA approval this quarter, and worldwide “as quickly as possible.”
However, the treatment can lead to serious side effects, such as edema or cerebral hemorrhage. Three participants in the clinical trial have died, according to the statement.
“When the full results are published” in a scientific journal, “we can begin to carefully weigh the risks and benefits, and that will help decide whether donanemab should be given routinely to patients,” commented Dr. Charles Marshall, from Queen Mary University of London.
Alzheimer’s disease is a neurodegenerative disease that affects tens of millions of people worldwide, and for which there is no treatment allowing a complete cure. First characterized by memory loss, patients gradually lose the ability to live normally.
While the exact cause of Alzheimer’s disease remains poorly understood, patients’ brains show amyloid plaques, which form around their neurons and eventually destroy them.
1683179865
#Promising #Results #Alzheimers #Treatment